Literature DB >> 28222221

Elastase-2, an angiotensin II-generating enzyme, contributes to increased angiotensin II in resistance arteries of mice with myocardial infarction.

Christiane Becari1,2,3, Marcondes A B Silva1, Marina T Durand2,4, Cibele M Prado5, Eduardo B Oliveira6, Mauricio S Ribeiro7, Helio C Salgado2, Maria Cristina O Salgado1, Rita C Tostes1.   

Abstract

BACKGROUND AND
PURPOSE: Angiotensin II (Ang II), whose generation largely depends on angiotensin-converting enzyme (ACE) activity, mediates most of the renin-angiotensin-system (RAS) effects. Elastase-2 (ELA-2), a chymotrypsin-serine protease elastase family member 2A, alternatively generates Ang II in rat arteries. Myocardial infarction (MI) leads to intense RAS activation, but mechanisms involved in Ang II-generation in resistance arteries are unknown. We hypothesized that ELA-2 contributes to vascular Ang II generation and cardiac damage in mice subjected to MI. EXPERIMENTAL APPROACH: Concentration-effect curves to Ang I and Ang II were performed in mesenteric resistance arteries from male wild type (WT) and ELA-2 knockout (ELA-2KO) mice subjected to left anterior descending coronary artery ligation (MI). KEY
RESULTS: MI size was similar in WT and ELA-2KO mice. Ejection fraction and fractional shortening after MI similarly decreased in both strains. However, MI decreased stroke volume and cardiac output in WT, but not in ELA-2KO mice. Ang I-induced contractions increased in WT mice subjected to MI (MI-WT) compared with sham-WT mice. No differences were observed in Ang I reactivity between arteries from ELA-2KO and ELA-2KO subjected to MI (MI-ELA-2KO). Ang I contractions increased in arteries from MI-WT versus MI-ELA-2KO mice. Chymostatin attenuated Ang I-induced vascular contractions in WT mice, but did not affect Ang I responses in ELA-2KO arteries. CONCLUSIONS AND IMPLICATIONS: These results provide the first evidence that ELA-2 contributes to increased Ang II formation in resistance arteries and modulates cardiac function after MI, implicating ELA-2 as a key player in ACE-independent dysregulation of the RAS.
© 2017 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28222221      PMCID: PMC5406290          DOI: 10.1111/bph.13755

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  57 in total

Review 1.  Peptidic regulation of heart rate and interactions with the autonomic nervous system.

Authors:  P Beaulieu; C Lambert
Journal:  Cardiovasc Res       Date:  1998-03       Impact factor: 10.787

2.  Angiotensin-converting enzyme inhibition augments the expression of rat elastase-2, an angiotensin II-forming enzyme.

Authors:  Christiane Becari; Felipe R Teixeira; Eduardo B Oliveira; Maria Cristina O Salgado
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-20       Impact factor: 4.733

3.  Role of elastase-2 as an angiotensin II-forming enzyme in rat carotid artery.

Authors:  Christiane Becari; Disney O Sivieri; Carlos F Santos; Milene K Moysés; Eduardo B Oliveira; Maria Cristina O Salgado
Journal:  J Cardiovasc Pharmacol       Date:  2005-10       Impact factor: 3.105

Review 4.  Vascular dysfunction and heart failure: epiphenomenon or etiologic agent?

Authors:  Zhi You Fang; Thomas H Marwick
Journal:  Am Heart J       Date:  2002-03       Impact factor: 4.749

5.  Angiotensinergic and noradrenergic neurons in the rat and human heart.

Authors:  Jaspal Patil; Silvan Stucki; Juerg Nussberger; Thomas Schaffner; Susanne Gygax; Juergen Bohlender; Hans Imboden
Journal:  Regul Pept       Date:  2010-12-09

6.  Conversion of renin substrate tetradecapeptide to angiotensin II by rat MAB elastase-2.

Authors:  Carlos F Santos; Andrew S Greene; Maria Cristina O Salgado; Eduardo B Oliveira
Journal:  Can J Physiol Pharmacol       Date:  2004-11       Impact factor: 2.273

7.  Inhibition of human pancreatic elastase 2 by peptide chloromethyl ketones.

Authors:  C Largman; E G DelMar; J W Brodrick; M Fassett; M C Geokas
Journal:  Biochim Biophys Acta       Date:  1980-07-10

8.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

9.  Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure.

Authors:  P F Binkley; G J Haas; R C Starling; E Nunziata; P A Hatton; C V Leier; R J Cody
Journal:  J Am Coll Cardiol       Date:  1993-03-01       Impact factor: 24.094

10.  Angiotensin I conversion by human and rat chymotryptic proteinases.

Authors:  B U Wintroub; N B Schechter; G S Lazarus; C E Kaempfer; L B Schwartz
Journal:  J Invest Dermatol       Date:  1984-11       Impact factor: 8.551

View more
  3 in total

1.  Elastase-2 Knockout Mice Display Anxiogenic- and Antidepressant-Like Phenotype: Putative Role for BDNF Metabolism in Prefrontal Cortex.

Authors:  C R A F Diniz; C Becari; A Lesnikova; C Biojone; M C O Salgado; H C Salgado; L B M Resstel; F S Guimarães; E Castrén; P C Casarotto; S R L Joca
Journal:  Mol Neurobiol       Date:  2018-01-30       Impact factor: 5.590

2.  Elastase-2, a Tissue Alternative Pathway for Angiotensin II Generation, Plays a Role in Circulatory Sympathovagal Balance in Mice.

Authors:  Christiane Becari; Marina T Durand; Alessander O Guimaraes; Renata M Lataro; Cibele M Prado; Mauro de Oliveira; Sarai C O Candido; Paloma Pais; Mauricio S Ribeiro; Michael Bader; Joao B Pesquero; Maria C O Salgado; Helio C Salgado
Journal:  Front Physiol       Date:  2017-03-23       Impact factor: 4.566

Review 3.  Molecular Mechanisms Involved in Intrarenal Renin-Angiotensin and Alternative Pathways in Diabetic Nephropathy - A Review.

Authors:  Elham Bahreini; Yousef Rezaei-Chianeh; Mohsen Nabi-Afjadi
Journal:  Rev Diabet Stud       Date:  2021-05-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.